Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

HRTX

Heron Therapeutics Inc

Feb 06 • 04:00PM ET

1.26

+0.05 4.13 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC ITOT PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	0.95%	Shs Outstand	183.32M	Perf Week	-4.55%
Market Cap	231.04M	Forward P/E	-	EPS next Y	0.00	Insider Trans	238.45%	Shs Float	181.62M	Perf Month	0.00%
Enterprise Value	323.85M	PEG	-	EPS next Q	-0.02	Inst Own	84.46%	Short Float	19.54%	Perf Quarter	13.51%
Income	-13.58M	P/S	1.49	EPS this Y	-11.11%	Inst Trans	3.90%	Short Ratio	20.12	Perf Half Y	-31.52%
Sales	155.10M	P/B	32.89	EPS next Y	100.00%	ROA	-5.78%	Short Interest	35.49M	Perf YTD	-3.08%
Book/sh	0.04	P/C	4.16	EPS next 5Y	-	ROE	-	52W High	2.68 -52.99%	Perf Year	-31.89%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	65.87% 48.68%	ROIC	-8.79%	52W Low	1.00 26.01%	Perf 3Y	-53.33%
Dividend Est.	-	EV/EBITDA	72.61	Sales past 3/5Y	18.67% -0.23%	Gross Margin	73.92%	Volatility	7.24% 6.03%	Perf 5Y	-93.12%
Dividend TTM	-	EV/Sales	2.09	EPS Y/Y TTM	58.23%	Oper. Margin	1.35%	ATR (14)	0.08	Perf 10Y	-94.00%
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	12.60%	Profit Margin	-8.75%	RSI (14)	41.69	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.56	EPS Q/Q	-223.97%	SMA20	-9.84%	Beta	1.26	Target Price	4.50
Payout	-	Debt/Eq	9.44	Sales Q/Q	16.47%	SMA50	-5.05%	Rel Volume	0.65	Prev Close	1.21
Employees	122	LT Debt/Eq	9.39	Earnings	Nov 04 BMO	SMA200	-19.17%	Avg Volume	1.76M	Price	1.26
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	-566.67% -2.10%	Trades		Volume	1,138,877	Change	4.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

Jan-10-26 09:35AM	Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M (TipRanks)
Jan-09-26 09:29AM	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth (GlobeNewswire) +9.45%
Dec-04-25 08:15AM	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire)
Nov-04-25 04:06PM	Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Loading…
09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:13AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress (GlobeNewswire)
Oct-29-25 05:58PM	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors (GlobeNewswire)
Oct-21-25 04:20PM	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire) -8.46%
Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Loading…
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
10:01AM	Loading…
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95% +7.00%

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Aug 08 '25	Buy	1.50	2,387,225	3,580,838	29,100,728	Aug 12 06:00 PM
Morgan Adam	Director	Aug 08 '25	Buy	1.50	1,766,546	2,649,819	8,753,290	Aug 12 05:02 PM

Open in Screener

XAIR

Beyond Air Inc

Feb 06 • 04:00PM ET

1.15

+0.11 10.05 %

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT ISRG SYK BSX EW INSP PEN NVCR TMDX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-7.53	Insider Own	5.88%	Shs Outstand	8.01M	Perf Week	-3.36%
Market Cap	9.21M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	0.00%	Shs Float	7.54M	Perf Month	38.72%
Enterprise Value	10.51M	PEG	-	EPS next Q	-0.75	Inst Own	18.31%	Short Float	32.30%	Perf Quarter	-38.83%
Income	-36.70M	P/S	1.59	EPS this Y	72.16%	Inst Trans	-2.86%	Short Ratio	0.33	Perf Half Y	-59.51%
Sales	5.80M	P/B	0.72	EPS next Y	46.31%	ROA	-87.40%	Short Interest	2.44M	Perf YTD	58.40%
Book/sh	1.59	P/C	0.85	EPS next 5Y	73.05%	ROE	-179.63%	52W High	10.40 -88.94%	Perf Year	-85.26%
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	25.75% 17.29%	ROIC	-152.16%	52W Low	0.67 70.80%	Perf 3Y	-99.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 21.66%	Gross Margin	-6.69%	Volatility	9.70% 19.15%	Perf 5Y	-99.03%
Dividend TTM	-	EV/Sales	1.81	EPS Y/Y TTM	73.23%	Oper. Margin	-575.72%	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.73	Sales Y/Y TTM	147.74%	Profit Margin	-632.51%	RSI (14)	45.70	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	77.97%	SMA20	-19.28%	Beta	0.40	Target Price	10.33
Payout	-	Debt/Eq	0.93	Sales Q/Q	127.82%	SMA50	-1.35%	Rel Volume	0.04	Prev Close	1.04
Employees	61	LT Debt/Eq	0.89	Earnings	Feb 13 BMO	SMA200	-53.66%	Avg Volume	7.38M	Price	1.15
IPO	Sep 23, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-61.64% -15.27%	Trades		Volume	328,949	Change	10.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-25	Initiated	D. Boral Capital	Buy	$11
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Feb-04-26 08:00AM	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 (GlobeNewswire) -5.22%
Jan-27-26 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -7.53% -5.93%
Jan-26-26 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire) -9.88%
Jan-14-26 08:30AM	Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.16%
Jan-13-26 01:40PM	Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments (Benzinga) +150.00%
07:30AM	Loading…
07:30AM	XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership (GlobeNewswire)
Dec-30-25 07:30AM	Beyond Air Appoints Dan Moorhead as Chief Financial Officer (GlobeNewswire)
Dec-17-25 07:30AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Germany and Brazil (GlobeNewswire)
Nov-26-25 04:30PM	Beyond Air Announces Transition of Chief Financial Officer (GlobeNewswire)
Nov-11-25 12:02AM	Beyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com) -16.09%
Nov-10-25 04:05PM	Beyond Air Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-25 08:00AM	Beyond Air Secures Up to $32 Million to Accelerate Growth (GlobeNewswire)
Oct-23-25 08:00AM	Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Sep-22-25 08:00AM	Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference (GlobeNewswire) +5.38%
Sep-08-25 03:55PM	Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds (GlobeNewswire) +49.77%
08:00AM	Loading…
08:00AM	NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults (GlobeNewswire)
Sep-03-25 08:00AM	Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:00AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan (GlobeNewswire) -6.55%
Aug-13-25 03:11AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... (GuruFocus.com) -22.47%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Beyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:45AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.63%
Jul-25-25 08:00AM	Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-22-25 07:30AM	Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. (GlobeNewswire)
Jun-26-25 09:55AM	Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher (Zacks) -6.47%
Jun-18-25 03:01AM	Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ... (GuruFocus.com) -29.02%
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +58.69%
04:01PM	Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-16-25 09:16AM	Beyond Air Inc (XAIR) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Loading…
08:00AM	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit PH (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
May-28-25 05:20PM	Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-20-25 08:00AM	Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-24-25 04:05PM	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) (GlobeNewswire)
Apr-21-25 04:05PM	NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism (GlobeNewswire)
Apr-15-25 04:05PM	NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board (GlobeNewswire)
Apr-09-25 04:05PM	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit GO at Home (GlobeNewswire) +11.63%
Apr-01-25 08:00AM	NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders (GlobeNewswire) -8.22%
Mar-31-25 08:00AM	Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site (GlobeNewswire)
Mar-24-25 04:05PM	NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy (GlobeNewswire) +5.63%
Mar-23-25 08:38AM	Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-11-25 07:30AM	Beyond Air Announces Agreements Expanding Global Distribution of LungFit PH (GlobeNewswire)
Mar-06-25 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.06%
Feb-10-25 04:05PM	Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.37% -6.49%
Feb-07-25 07:10AM	Beyond Air Inc (XAIR) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-05-25 09:29AM	Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-27-25 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) -7.83%
Jan-24-25 09:15AM	Beyond Air Announces LungFit PH Receives Market Authorization in Australia (GlobeNewswire)
Jan-06-25 08:00AM	Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire)
Dec-03-24 04:05PM	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy (GlobeNewswire) +7.85% -8.67%
Dec-02-24 07:30AM	Beyond Air Receives CE Mark in Europe for the LungFit PH System (GlobeNewswire)
Nov-26-24 07:30AM	NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board (GlobeNewswire) +22.16%
Nov-14-24 04:05PM	Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.71% -5.38%
Nov-11-24 04:05PM	Beyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.64%
07:00AM	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-08-24 07:06AM	Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.86%
Oct-29-24 04:22PM	Beyond Air Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) +11.65% +8.78%
Oct-07-24 07:00AM	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.45%
Oct-02-24 07:30AM	Beyond Air Partners with Healthcare Links to Expand Access to LungFit PH System Through Group Purchasing Organizations and Integrated Delivery Networks (GlobeNewswire) +10.57%
Sep-28-24 07:40AM	Beyond Air to sell 40.39M shares at 51c in private placement (TipRanks)
07:35AM	Beyond Air terminates loan, security agreements with Avenue Capital (TipRanks)
Sep-27-24 07:34AM	Beyond Air Provides LungFit PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed (GlobeNewswire)
07:32AM	Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital (GlobeNewswire)
07:30AM	Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Sep-23-24 08:00AM	Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -6.08%
Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%
08:28AM	Why Is Beyond Air (XAIR) Stock Down 22% Today? (InvestorPlace)
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-24-24 08:53PM	XAIR Stock Earnings: Beyond Air Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +8.06%
05:25PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Beyond Air Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-13-24 04:05PM	Beyond Air Appoints David Webster as Chief Commercial Officer (GlobeNewswire)
Jun-03-24 07:00AM	Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) (GlobeNewswire) -8.59%
May-23-24 04:09PM	Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -9.50%
May-01-24 07:00AM	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-21-24 12:00PM	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.84%
Mar-20-24 09:00AM	Beyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Feb-13-24 08:51AM	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript (Insider Monkey) -17.67%
Feb-12-24 04:05PM	Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 (GlobeNewswire) +14.97%
Jan-18-24 08:00AM	Beyond Air Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -5.02%
Dec-27-23 07:30AM	Beyond Cancer Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors (GlobeNewswire)
Dec-21-23 01:40AM	Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc (GuruFocus.com) +12.04%
Nov-15-23 04:05PM	Beyond Air To Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +23.57% -8.96%
Nov-14-23 10:00AM	Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript (Insider Monkey) -31.03%
Nov-13-23 04:05PM	Beyond Air Reports Financial Results for Second Quarter of Fiscal Year 2024 (GlobeNewswire)
Nov-03-23 12:00PM	Beyond Cancer Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire) -6.91%
Oct-19-23 04:05PM	Beyond Air Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-17-23 04:05PM	Beyond Air To Participate in the Truist Securities BioPharma Symposium (GlobeNewswire) +8.48% -6.17%
07:30AM	Beyond Cancer Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice (GlobeNewswire)
Oct-16-23 07:30AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
07:00AM	Beyond Air Receives Innovative Technology Contract from Vizient for LungFit PH (GlobeNewswire)
Oct-04-23 07:30AM	Beyond Cancer Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-23 04:05PM	Beyond Air To Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -7.79%

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lisi Steven A.	CEO and Chairman of the Board	Jul 21 '25	Buy	3.25	6,000	19,491	3,327,411	Jul 23 04:05 PM
Carey Robert	Director	Mar 14 '25	Buy	0.25	1,000,000	250,050	4,076,864	Mar 17 08:15 AM
Gaul Michael A.	Chief Operating Officer	Feb 19 '25	Buy	0.38	6,000	2,294	94,150	Feb 21 05:00 PM

HRTX

Heron Therapeutics Inc

XAIR

Beyond Air Inc

Upgrade your FINVIZ experience